Pulmonary Arterial Hypertension Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Growing of the Incidences of Cardiovascular and Pulmonary Disorders
   3. Market Restraints
      1. Limited Treatment Options
      2. High Cost of Therapy
   4. Market Opportunities
      1. Substantial Research and Development (R&D) Activities
   5. Market Trends
      1. Shift Towards Combination Therapies
      2. Focus on Personalized Medicine
5. MARKET SEGMENTATION
   1. By Drug Type
      1. Endothelin Receptor Antagonists (ERAs)
      2. Phosphodiesterase-5 (PDE -5) Inhibitors
      3. Soluble Guanylate Cyclase (sGC) Stimulators
      4. Prostacyclin Analogue
      5. Calcium Channel Blockers
      6. Others
   2. By Route of Administration
      1. Oral
      2. Inhaled
      3. Intravenous
      4. Subcutaneous
   3. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   4. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Amneal Pharmaceutical Inc.
      2. Actelion Pharmaceuticals US, Inc.
      3. Dr. Reddy's Laboratories Ltd
      4. Gilead Sciences, Inc.
      5. GlaxoSmithKline PLC.
      6. Hikma Pharmaceuticals PLC
      7. Mylan N.V.
      8. Natco Pharma Ltd.
      9. Pfizer Inc.
      10. Par Pharmaceutical.
      11. Sun Pharmaceutical Industries Ltd.
      12. Sigmapharm Laboratories, LLC.
      13. Sandoz AG
      14. Teva Pharmaceuticals Industries Ltd.
      15. United Therapeutics Corp.
      16. Zydus Pharmaceutical USA
   2. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Pulmonary Arterial Hypertensionmarket?

The global market of Pulmonary Arterial Hypertension is projected to reach USD 12.96Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Pulmonary Arterial Hypertensionmarket?

The global Pulmonary Arterial Hypertension market has an estimated annual growth rate of 5.4%.

Q.3. What are the recent trends of Pulmonary Arterial Hypertensionmarket?

Shift towards combination therapies and focus on personalized medicineare some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Pulmonary Arterial Hypertension?

The major companies profiled in this report include Amneal Pharmaceutical Inc., Actelion Pharmaceuticals US, Inc., Dr. Reddy's Laboratories Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC., Hikma Pharmaceuticals PLC, Mylan N.V., Natco Pharma Ltd., Pfizer Inc., Par Pharmaceutical., Sun Pharmaceutical Industries Ltd., Sigmapharm Laboratories, LLC., Sandoz AG, Teva Pharmaceuticals Industries Ltd., United Therapeutics Corp., Zydus Pharmaceutical USA, among others.

Q.5. Which region is estimated to held highest CAGR inPulmonary Arterial Hypertensionmarket?

North America is estimated to hold biggest share in the market for Pulmonary Arterial Hypertension.